An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
BACKGROUND: The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive d...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797079830391422976 |
|---|---|
| author | Vickers, A Till, C Tangen, C Lilja, H Thompson, I |
| author_facet | Vickers, A Till, C Tangen, C Lilja, H Thompson, I |
| author_sort | Vickers, A |
| collection | OXFORD |
| description | BACKGROUND: The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive digital rectal exam (DRE). METHODS: To evaluate the current guideline, we compared the area under the curve of a multivariable model for prostate cancer including age, PSA, DRE, family history, and prior biopsy, with and without PSA velocity, in 5519 men undergoing biopsy, regardless of clinical indication, in the control arm of the Prostate Cancer Prevention Trial. We also evaluated the clinical implications of using PSA velocity cut points to determine biopsy in men with low PSA and negative DRE in terms of additional cancers found and unnecessary biopsies conducted. All statistical tests were two-sided. RESULTS: Incorporation of PSA velocity led to a very small increase in area under the curve from 0.702 to 0.709. Improvements in predictive accuracy were smaller for the endpoints of high-grade cancer (Gleason score of 7 or greater) and clinically significant cancer (Epstein criteria). Biopsying men with high PSA velocity but no other indication would lead to a large number of additional biopsies, with close to one in seven men being biopsied. PSA cut points with a comparable specificity to PSA velocity cut points had a higher sensitivity (23% vs 19%), particularly for high-grade (41% vs 25%) and clinically significant (32% vs 22%) disease. These findings were robust to the method of calculating PSA velocity. CONCLUSIONS: We found no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines. |
| first_indexed | 2024-03-07T00:51:25Z |
| format | Journal article |
| id | oxford-uuid:86885891-e142-4b97-ada5-92587e49f56b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:51:25Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:86885891-e142-4b97-ada5-92587e49f56b2022-03-26T22:04:36ZAn empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:86885891-e142-4b97-ada5-92587e49f56bEnglishSymplectic Elements at Oxford2011Vickers, ATill, CTangen, CLilja, HThompson, I BACKGROUND: The National Comprehensive Cancer Network and American Urological Association guidelines on early detection of prostate cancer recommend biopsy on the basis of high prostate-specific antigen (PSA) velocity, even in the absence of other indications such as an elevated PSA or a positive digital rectal exam (DRE). METHODS: To evaluate the current guideline, we compared the area under the curve of a multivariable model for prostate cancer including age, PSA, DRE, family history, and prior biopsy, with and without PSA velocity, in 5519 men undergoing biopsy, regardless of clinical indication, in the control arm of the Prostate Cancer Prevention Trial. We also evaluated the clinical implications of using PSA velocity cut points to determine biopsy in men with low PSA and negative DRE in terms of additional cancers found and unnecessary biopsies conducted. All statistical tests were two-sided. RESULTS: Incorporation of PSA velocity led to a very small increase in area under the curve from 0.702 to 0.709. Improvements in predictive accuracy were smaller for the endpoints of high-grade cancer (Gleason score of 7 or greater) and clinically significant cancer (Epstein criteria). Biopsying men with high PSA velocity but no other indication would lead to a large number of additional biopsies, with close to one in seven men being biopsied. PSA cut points with a comparable specificity to PSA velocity cut points had a higher sensitivity (23% vs 19%), particularly for high-grade (41% vs 25%) and clinically significant (32% vs 22%) disease. These findings were robust to the method of calculating PSA velocity. CONCLUSIONS: We found no evidence to support the recommendation that men with high PSA velocity should be biopsied in the absence of other indications; this measure should not be included in practice guidelines. |
| spellingShingle | Vickers, A Till, C Tangen, C Lilja, H Thompson, I An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
| title | An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
| title_full | An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
| title_fullStr | An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
| title_full_unstemmed | An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
| title_short | An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
| title_sort | empirical evaluation of guidelines on prostate specific antigen velocity in prostate cancer detection |
| work_keys_str_mv | AT vickersa anempiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT tillc anempiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT tangenc anempiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT liljah anempiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT thompsoni anempiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT vickersa empiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT tillc empiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT tangenc empiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT liljah empiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection AT thompsoni empiricalevaluationofguidelinesonprostatespecificantigenvelocityinprostatecancerdetection |